174 related articles for article (PubMed ID: 28105015)
1. The Potassium Channel KCa3.1 Represents a Valid Pharmacological Target for Astrogliosis-Induced Neuronal Impairment in a Mouse Model of Alzheimer's Disease.
Wei T; Yi M; Gu W; Hou L; Lu Q; Yu Z; Chen H
Front Pharmacol; 2016; 7():528. PubMed ID: 28105015
[TBL] [Abstract][Full Text] [Related]
2. Ca
Yu Z; Dou F; Wang Y; Hou L; Chen H
J Neuroinflammation; 2018 Nov; 15(1):316. PubMed ID: 30442153
[TBL] [Abstract][Full Text] [Related]
3. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
4. KCa3.1 Inhibition Switches the Astrocyte Phenotype during Astrogliosis Associated with Ischemic Stroke Via Endoplasmic Reticulum Stress and MAPK Signaling Pathways.
Yu Z; Yi M; Wei T; Gao X; Chen H
Front Cell Neurosci; 2017; 11():319. PubMed ID: 29075181
[TBL] [Abstract][Full Text] [Related]
5. The potassium channel KCa3.1 constitutes a pharmacological target for astrogliosis associated with ischemia stroke.
Yi M; Wei T; Wang Y; Lu Q; Chen G; Gao X; Geller HM; Chen H; Yu Z
J Neuroinflammation; 2017 Oct; 14(1):203. PubMed ID: 29037241
[TBL] [Abstract][Full Text] [Related]
6. KCa3.1 deficiency attenuates neuroinflammation by regulating an astrocyte phenotype switch involving the PI3K/AKT/GSK3β pathway.
Wei T; Wang Y; Xu W; Liu Y; Chen H; Yu Z
Neurobiol Dis; 2019 Dec; 132():104588. PubMed ID: 31470105
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of KCa3.1 attenuates TGF-β-induced reactive astrogliosis through the Smad2/3 signaling pathway.
Yu Z; Yu P; Chen H; Geller HM
J Neurochem; 2014 Jul; 130(1):41-49. PubMed ID: 24606313
[TBL] [Abstract][Full Text] [Related]
8. Role of transient receptor potential ankyrin 1 channels in Alzheimer's disease.
Lee KI; Lee HT; Lin HC; Tsay HJ; Tsai FC; Shyue SK; Lee TS
J Neuroinflammation; 2016 Apr; 13(1):92. PubMed ID: 27121378
[TBL] [Abstract][Full Text] [Related]
9. Activation of the KCa3.1 channel contributes to traumatic scratch injury-induced reactive astrogliosis through the JNK/c-Jun signaling pathway.
Yi M; Dou F; Lu Q; Yu Z; Chen H
Neurosci Lett; 2016 Jun; 624():62-71. PubMed ID: 27163196
[TBL] [Abstract][Full Text] [Related]
10. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.
Button EB; Boyce GK; Wilkinson A; Stukas S; Hayat A; Fan J; Wadsworth BJ; Robert J; Martens KM; Wellington CL
Alzheimers Res Ther; 2019 May; 11(1):44. PubMed ID: 31084613
[TBL] [Abstract][Full Text] [Related]
11. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF-β/Smad2/STAT3 signaling.
Zheng JY; Sun J; Ji CM; Shen L; Chen ZJ; Xie P; Sun YZ; Yu RT
Neurobiol Aging; 2017 Jun; 54():112-132. PubMed ID: 28366226
[TBL] [Abstract][Full Text] [Related]
12. Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer's disease.
Lee HT; Lee KI; Chen CH; Lee TS
J Neuroinflammation; 2019 Dec; 16(1):267. PubMed ID: 31847859
[TBL] [Abstract][Full Text] [Related]
13. The potassium channel KCa3.1 represents a valid pharmacological target for microgliosis-induced neuronal impairment in a mouse model of Parkinson's disease.
Lu J; Dou F; Yu Z
J Neuroinflammation; 2019 Dec; 16(1):273. PubMed ID: 31878950
[TBL] [Abstract][Full Text] [Related]
14. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.
Jin LW; Lucente JD; Nguyen HM; Singh V; Singh L; Chavez M; Bushong T; Wulff H; Maezawa I
Ann Clin Transl Neurol; 2019 Apr; 6(4):723-738. PubMed ID: 31019997
[TBL] [Abstract][Full Text] [Related]
15. Oleanolic acid protects against cognitive decline and neuroinflammation-mediated neurotoxicity by blocking secretory phospholipase A2 IIA-activated calcium signals.
Zhang L; Xia R; Jia J; Wang L; Li K; Li Y; Zhang J
Mol Immunol; 2018 Jul; 99():95-103. PubMed ID: 29747052
[TBL] [Abstract][Full Text] [Related]
16. Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease.
Beggiato S; Cassano T; Ferraro L; Tomasini MC
Life Sci; 2020 Sep; 257():118037. PubMed ID: 32622942
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model.
Reichenbach N; Delekate A; Plescher M; Schmitt F; Krauss S; Blank N; Halle A; Petzold GC
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30617153
[TBL] [Abstract][Full Text] [Related]
18. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease.
Olsen M; Aguilar X; Sehlin D; Fang XT; Antoni G; Erlandsson A; Syvänen S
Mol Imaging Biol; 2018 Aug; 20(4):605-614. PubMed ID: 29297157
[TBL] [Abstract][Full Text] [Related]
19. Chronic Intermittent Hypoxia Induces Robust Astrogliosis in an Alzheimer's Disease-Relevant Mouse Model.
Macheda T; Roberts K; Lyons DN; Higgins E; Ritter KJ; Lin AL; Alilain WJ; Bachstetter AD
Neuroscience; 2019 Feb; 398():55-63. PubMed ID: 30529693
[TBL] [Abstract][Full Text] [Related]
20. Methyl Salicylate Lactoside Protects Neurons Ameliorating Cognitive Disorder Through Inhibiting Amyloid Beta-Induced Neuroinflammatory Response in Alzheimer's Disease.
Li J; Ma X; Wang Y; Chen C; Hu M; Wang L; Fu J; Shi G; Zhang D; Zhang T
Front Aging Neurosci; 2018; 10():85. PubMed ID: 29636677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
